It was confirmed in primary AML cells that a long-term inhibition of FLT3-ITD by quizartinib inhibited RSK NTKD, as well as PDK1, and reduced RSK1 expression, while LJH685 inhibited RSK NTKD and reduced RSK2 expression (Figure 3I). This evidence concerns the gene RPS6KA1 and acute myeloid leukemia.